Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)

Peer Review reports

Original Submission
12 Apr 2019	Submitted	Original manuscript
27 Apr 2019	Reviewed	Reviewer Report - Masaki Shiota
7 May 2019	Reviewed	Reviewer Report - Hyonok Yoon
28 Jun 2019	Author responded	Author comments - Javier Puente
Resubmission - Version 2
28 Jun 2019	Submitted	Manuscript version 2
2 Jul 2019	Reviewed	Reviewer Report - Masaki Shiota
4 Jul 2019	Reviewed	Reviewer Report - Hyonok Yoon
21 Jul 2019	Author responded	Author comments - Javier Puente
Resubmission - Version 3
21 Jul 2019	Submitted	Manuscript version 3
Publishing
23 Jul 2019	Editorially accepted
5 Aug 2019	Article published	10.1186/s12885-019-5974-9

Back to article page